Skip to main content
. 2019 Aug 30;85(11):2512–2523. doi: 10.1111/bcp.14063

Figure 3.

Figure 3

Liraglutide reduced systemic proinflammatory markers, here shown as relative differences in comparison to placebo. The reduction reached significance for interleukin (IL)‐6; however, a similar numerical trend was present for other proinflammatory cytokines, suggesting a potential systemic anti‐inflammatory effect of the glucagon‐like peptide‐1‐agonist. The error bars illustrate the 95% confidence intervals. IFN = interferon; TNF = tumour necrosis factor